T-lymphocytes in B-cell chronic lymphocytic leukaemia

Hypergranular promyelocytic leukemia: correlation between morphology and chromosomal translocations including t(15;17) and t(11;17).

Leukemia·2000

The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group.

British journal of haematology·1994

P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?

Leukemia·1994

Monoclonal antibody Ki-67 identifies B and T cells in cycle in chronic lymphocytic leukemia: correlation with disease activity.

Leukemia·1992

Translocation t(11;14)(q13;q32) in chronic lymphoid disorders.

Genes, chromosomes & cancer·1992

Haematological differences between chronic granulocytic leukaemia, atypical chronic myeloid leukaemia, and chronic myelomonocytic leukaemia.

Leukemia & lymphoma·1992

Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia.

Haematologica·2026

Risks and benefits of gene therapy and transplantation in sickle cell disease. Comment on: "HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial"

Haematologica·2026

Balancing remission durability and treatment burden in older acute myeloid leukemia. Comment on: "Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia".

Haematologica·2026

Separating dose schedule from disease biology in CD19 CAR T-cell therapy. Comment on: "A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma".

Haematologica·2026

Safety, feasibility, and efficacy of anti-PD-1 therapy for the treatment of classical Hodgkin lymphoma.

Haematologica·2026

Defining the therapeutic window of NLRP6 modulation in graft-versus-host disease. Comment on: "NLRP6 regulates donor T cell activation and acute graft-versus-host disease via ZAP-70-Erk pathway".

Haematologica·2026

Intraoperative Imprint Cytology Versus Frozen Section for Sentinel Lymph Node Assessment in Breast Carcinoma: A Prospective Diagnostic Accuracy Study From a Resource-Limited Setting in Eastern India.

Cureus·2026

ASO Editorial: Lymph Node Dissection in the Immunotherapy Era: Friend or Foe?

Annals of surgical oncology·2026

[Analysis of clinicopathological and immunological characteristics of patients with acquired immune deficiency syndrome-associated diffuse large B-cell lymphoma complicated by Talaromyces marneffei infection].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2026

Real-World Experience With TRBC1 Immunohistochemistry Across Cutaneous T-Cell Lymphoma Subtypes:A Large Cohort Study.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026

Haematopoietic stem cell transplantation in hepatosplenic T-cell lymphoma: a retrospective analysis of the EBMT Lymphoma Working Party.

The Lancet. Haematology·2026

Phase II trial of First-Line Axitinib Plus Nivolumab in Patients with Advanced Mucosal Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Videos

T-lymphocytes in B-cell chronic lymphocytic leukaemia

Related Concept Videos

Hypergranular promyelocytic leukemia: correlation between morphology and chromosomal translocations including t(15;17) and t(11;17).

The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group.

P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?

Monoclonal antibody Ki-67 identifies B and T cells in cycle in chronic lymphocytic leukemia: correlation with disease activity.

Translocation t(11;14)(q13;q32) in chronic lymphoid disorders.

Haematological differences between chronic granulocytic leukaemia, atypical chronic myeloid leukaemia, and chronic myelomonocytic leukaemia.

Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia.

Risks and benefits of gene therapy and transplantation in sickle cell disease. Comment on: "HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial"

Balancing remission durability and treatment burden in older acute myeloid leukemia. Comment on: "Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia".

Separating dose schedule from disease biology in CD19 CAR T-cell therapy. Comment on: "A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma".

Safety, feasibility, and efficacy of anti-PD-1 therapy for the treatment of classical Hodgkin lymphoma.

Defining the therapeutic window of NLRP6 modulation in graft-versus-host disease. Comment on: "NLRP6 regulates donor T cell activation and acute graft-versus-host disease via ZAP-70-Erk pathway".

Intraoperative Imprint Cytology Versus Frozen Section for Sentinel Lymph Node Assessment in Breast Carcinoma: A Prospective Diagnostic Accuracy Study From a Resource-Limited Setting in Eastern India.

ASO Editorial: Lymph Node Dissection in the Immunotherapy Era: Friend or Foe?

[Analysis of clinicopathological and immunological characteristics of patients with acquired immune deficiency syndrome-associated diffuse large B-cell lymphoma complicated by Talaromyces marneffei infection].

Real-World Experience With TRBC1 Immunohistochemistry Across Cutaneous T-Cell Lymphoma Subtypes:A Large Cohort Study.

Haematopoietic stem cell transplantation in hepatosplenic T-cell lymphoma: a retrospective analysis of the EBMT Lymphoma Working Party.

Phase II trial of First-Line Axitinib Plus Nivolumab in Patients with Advanced Mucosal Melanoma.

Related Experiment Videos

T-lymphocytes in B-cell chronic lymphocytic leukaemia

Related Concept Videos

Related Articles